Effects of long-term dienogest treatment on postoperative recurrence in ovarian endometrioma

Effects of long-term dienogest treatment on postoperative recurrence in ovarian endometrioma - Postoperative recurrence prevention by dienogest treatment in ovarian endometrioma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009819

Enrollment

120

Registered

2013-01-21

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian endometrioma

Interventions

Medicine: Dienogest Treatment length:1 year postoperation Dose: 2 mg per day Medicine: no treatment

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: A person who underwent a conservative surgery for ovarian endometrioma; cystectomy or ablation of ovarian endometrioma.

Exclusion criteria

Exclusion criteria: A person who has allergy for dienogest and who wish to bear children right now.

Design outcomes

Primary

Measure	Time frame
The primary outcome is to evaluate the effects of long-term dienogest treatment on postoperative recurrence in ovarian endometrioma.	—

Secondary

Measure	Time frame
The secondary outcome is to evaluate the effects of long-term dienogest treatment on postoperative recurrence of pain in ovarian endometrioma.	—

Countries

Japan

Contacts

Public ContactToshifumi Takahashi

Yamagata University, Faculty of Medicine Department of Obstetrics and Gynecology

totakaha@med.id.yamagata-u.ac.jp023-628-5393

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026